UVA Sunscreen with Invisicare Available For International Licensing
LAS VEGAS, July 29 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI)(http://www.skinvisible.com, http://www.invisicare.com), the developers of Invisicare, a patented polymer delivery system that enhances topical skincare products, announces the successful development of a new broad spectrum sunscreen combining the active ingredient avobenzone (Parsol(R) 1789) with Invisicare. Avobenzone is one of only two UVA (320-400 nm) sunscreens approved in the USA. It is on the FDA's Category I sunscreen list, as it offers broad-range UVA protection and helps protect the skin against the harmful effects of sun which can cause skin cancers and premature skin aging.
"The results of the studies for our SPF 30 and 50 sunscreens are very impressive," said James Roszell, PhD for Skinvisible Pharmaceuticals. "Avobenzone is notoriously unstable when exposed to light with most products only offering two to four hours of protection. Skinvisible's sunscreens with Invisicare achieved eight hours of photostability with minimal degradation. Additionally, Invisicare has the ability to hold ingredients like avobenzone on the skin for extended periods of time, while resisting wash-off and perspiration; rating our sunscreen formulas as "very water-resistant".
"The completions of our studies are timely as the FDA reviews new labeling standards," said Mr. Terry Howlett, President and CEO of Skinvisible. "The FDA proposed changes to sunscreen labeling so that consumers can easily identify which sunscreen products offer UVA and UVB protection and at what level. This four-star ranking of UVA protection levels ranges from "low," "medium," "high" to "highest". We foresee that Skinvisible's new broad spectrum sunscreen would achieve the "highest" rating."
In addition to sunscreens, Skinvisible has a portfolio of 25 topical dermatology products formulated with Invisicare available for world-wide licensing. In addition to developing proprietary products for clients, Skinvisible's formulations include prescription, over-the-counter and cosmetic products for the treatment of acne, atopic dermatitis, fungal infections, as well as anti-inflammatories, analgesics, hand sanitizers, anti-aging, and sunless tanning products.
Parsol(R) 1789 -- registered trademark of DSM Nutritional Products.
About Invisicare(R) -- Invisicare is Skinvisible's patented polymer delivery system that offers "life-cycle management" and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash-off and perspiration. Invisicare controls the release of actives, reducing irritation and eliminating some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. http://www.invisicare.com
About Skinvisible Pharmaceuticals, Inc. -- Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development, license, and royalties fees for the life of the Invisicare patent. http://www.skinvisible.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbors created thereby. Such statements involve
certain risks and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward looking
statements as a result of risk factors discussed in Skinvisible, Inc.
reports on file with the U.S. Securities and Exchange Commission
(including, but not limited to, a report on Form 10Q for the quarter ending
March 30, 2008)
Doreen McMorran, VP Business Development
Skinvisible Pharmaceuticals, Inc
|SOURCE Skinvisible, Inc.|
Copyright©2008 PR Newswire.
All rights reserved